Format

Send to

Choose Destination
Breast. 2014 Oct;23(5):683-9. doi: 10.1016/j.breast.2014.07.006. Epub 2014 Aug 19.

Smartphone breast applications - what's the evidence?

Author information

1
Department of Surgery & Cancer, Imperial College London, UK. Electronic address: m.mobasheri@imperial.ac.uk.
2
Department of Surgery & Cancer, Imperial College London, UK. Electronic address: m.johnston@imperial.ac.uk.
3
Institute of Global Health Innovation, Imperial College London, UK. Electronic address: dominic.king@imperial.ac.uk.
4
Institute of Global Health Innovation, Imperial College London, UK. Electronic address: d.leff@imperial.ac.uk.
5
Department of Breast Surgery, Imperial College London, UK. Electronic address: paul.thiruchelvam@ic.ac.uk.
6
Institute of Global Health Innovation, Imperial College London, UK. Electronic address: a.darzi@imperial.ac.uk.

Abstract

INTRODUCTION:

There are around 40,000 healthcare applications (apps) available for smartphones. Apps have been reviewed in many specialties. Breast cancer is the most common malignancy in females with almost 1.38 million new cases a year worldwide. Despite the high prevalence of breast disease, apps in this field have not been reviewed to date. We have evaluated apps relevant to breast disease with an emphasis on their evidence base (EB) and medical professional involvement (MPI).

METHODS:

Searching the major app stores (apple iTunes, Google Play, BlackBerry World, Windows Phone) using the most common breast symptoms and diseases identified relevant apps. Extracted data for each app included target consumer, disease focus, app function, documentation of any EB, documentation of MPI in development, and potential safety concerns.

RESULTS:

One-hundred-and-eighty-five apps were reviewed. The majority focused on breast cancer (n = 139, 75.1%). Educational (n = 94) and self-assessment tools (n = 30) were the most common functions demonstrated. EB and MPI was identified in 14.2% and 12.8% of apps respectively. Potential safety concerns were identified in 29 (15.7%) apps.

CONCLUSIONS:

There is a lack of EB and MPI in the development of current breast apps. Safety concerns highlight the need for regulation, full authorship disclosure and clinical trials. A robust framework for identifying high quality applications is necessary. This will address the current barrier pertaining to a lack of consumer confidence in their use and further aid to promote their widespread implementation within healthcare.

KEYWORDS:

Apps; Breast disease; Cancer; Mobile health; Smartphone; mHealth

PMID:
25153432
DOI:
10.1016/j.breast.2014.07.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center